Latest Headlines

  1. Peering Into The Mind Of Artificial Intelligence To Make Better Antibiotics 8/18/2024

    Artificial intelligence (AI) has exploded in popularity. It powers models that help us drive vehicles, proofread emails and even design new molecules for medications

  2. Moffitt Researchers Develop New Chemical Method To Enhance Drug Discovery 8/16/2024

    Moffitt Cancer Center researchers have developed a novel reagent that enhances the precision of drug synthesis

  3. Phanes Therapeutics' PT217 Receives Orphan Drug Designation For Neuroendocrine Carcinoma From The FDA 8/16/2024

    Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PT217 for the treatment of neuroendocrine carcinoma (NEC)

  4. Sanyou Bio's Innovative Intelligent Antibody Design oneClick+ Platform Is Officially Launched 8/15/2024

    On August 16, 2024 (local time), Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. officially announced the launch of the "Sanyou Innovative Intelligent Antibody Design oneClick+ Platform"

  5. Quantiphi Strengthens AI Drug Discovery, Development Collaboration With Transcell Through Strategic Minority Investment 8/13/2024

    Quantiphi, an award-winning AI-first digital engineering company today announced it has acquired a strategic minority interest in leading stem cell-based biotech innovator Transcell, marking a milestone in AI-supported drug discovery in the life sciences industry.

  6. Predictive Oncology Expands The Application Of Its Live-Cell Tumor Platform To De-Risk Drug Discovery And Accelerate Pipeline Development 8/13/2024

    Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced that it has expanded the available applications for its platform to account for patient heterogeneity, de-risk drug discovery, and accelerate pipeline development.

  7. QuEra Computing And Quantum Intelligence Corp Team Up To Accelerate Drug Discovery With Quantum Computing 8/13/2024

    QuEra Computing, the leader in neutral-atom quantum computing, and Quantum Intelligence Corp. (QIC), a South Korean pioneer in AI-driven drug development, have announced a strategic partnership.

  8. IASO Bio Receives U.S. FDA Approval Of Investigational New Drug Application For Equecabtagene Autoleucel For Two New Autoimmune Disease Indications 8/12/2024

    IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced that the investigational new drug (IND) application for its fully human anti-BCMA chimeric antigen receptor autologous T cell injection (Equecabtagene Autoleucel，Eque-cel) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of Non-renal Systemic Lupus Erythematosus (SLE) and Lupus Nephritis(LN)

  9. Absci Collaborates With Global Cancer Center To Discover Novel Therapeutics Using Generative AI 8/12/2024

    Today, Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a leading cancer treatment and research center, to discover and develop novel therapeutics using generative AI for up to six programs.

  10. scPharmaceuticals Announces FDA Approval Of Supplemental New Drug Application Expanding The FUROSCIX Indication In Heart Failure 8/12/2024

    scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the Food and Drug Administration (FDA) has approved its Supplemental New Drug Application (sNDA) seeking to expand the FUROSCIX indication for heart failure patients.